7,580.07

-140.32

-1.82%

51,770.31

-572.25

-1.09%

25,437.00

-747.73

-2.86%

2,811.84

-47.37

-1.66%

4.9290

-0.0600

-1.20%

19.42

+2.22

+12.91%

3,898.90

-132.50

-3.29%

77,351.37

-344.55

-0.44%

Crude Oil Dec 26

104.12

+2.12

+2.08%

US Private Equity

10,850.63

-82.20

-0.75%

NYSE American - Nasdaq Real Time Price USD

VolitionRx Limited (VNRX)

0.1953 -0.0022 (-1.11%)

At close: October 30 at 4:00:00 PM EDT

0.1919 -0.0034 (-1.74%)

After hours: October 30 at 6:36:20 PM EDT

Loading Chart for VNRX

Chart Range Bar

Interval:

In partnership with ChartIQ

VolitionRx Signs LOI with Missionpharma to explore the Development and Launch of Volition's Lateral Flow Technology for NETosis Worldwide

VolitionRx Signs LOI with Missionpharma to explore the Development and Launch of Volition's Lateral Flow Technology for NETosis Worldwide

VolitionRx Limited Announces $500,000 Partial Pre-Payment of Convertible Note in Cash

VolitionRx Limited Announces $500,000 Partial Pre-Payment of Convertible Note in Cash

VolitionRx Participates in Launch of DETECSEPS Program in France

VolitionRx Participates in Launch of DETECSEPS Program in France

VNRX: VolitionRx Prepays Outstanding Balance on the $7,500,000 Lind Senior Secured Convertible Promissory Note Dated May 20, 2025. Review of Papers, Posters, and Videos Released in Mid-2026. Sysmex Collaboration is the 3rd Recent Agreement in the Human Space.

VNRX: VolitionRx Prepays Outstanding Balance on the $7,500,000 Lind Senior Secured Convertible Promissory Note Dated May 20, 2025. Review of Papers, Posters, and Videos Released in Mid-2026. Sysmex Collaboration is the 3rd Recent Agreement in the Human Space.

VolitionRx Limited Announces Pre-Payment in Full of $7.5 million Senior Secured Convertible Promissory Note Due May 20, 2027

VolitionRx Limited Announces Pre-Payment in Full of $7.5 million Senior Secured Convertible Promissory Note Due May 20, 2027

Penny Stock VolitionRx Expands Addressable Markets With Key Diagnostic Validations

Penny Stock VolitionRx Expands Addressable Markets With Key Diagnostic Validations

VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets

VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets

Volition Announces Landmark Clinical Validation of Nu.Q® NETs Biomarker in Sepsis

Volition Announces Landmark Clinical Validation of Nu.Q® NETs Biomarker in Sepsis

Volition (VNRX) Q2 2026 Earnings Call Transcript

Volition (VNRX) Q2 2026 Earnings Call Transcript

Volition Reports Publication of First Peer Reviewed Paper on New Capture-Seq™ Liquid Biopsy Technology

Volition Reports Publication of First Peer Reviewed Paper on New Capture-Seq™ Liquid Biopsy Technology

Volition Advances Nu.Q® NETs Platform Towards Commercialization

Volition Advances Nu.Q® NETs Platform Towards Commercialization

Mobilize your Website

View Site in Mobile | Classic

Share by: